Tag: investigation

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Hong Kong, June 16, 2026 (GLOBE NEWSWIRE) -- JM Group Limited (“JM Group” or the “Company”), a Hong Kong-headquartered sourcing and wholesale solutions provider for a wide array of consumer products, today announced that on June 12, 2026, NYSE American LLC (“NYSE American” or the “Exchange”) publicly announced and provided a notice to the Company that the staff of NYSE Regulation (the “NYSE Regulation”) has determined to commence proceedings to delist the Company’s ordinary shares from NYSE American (the “Delisting Decision”).

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.